344 related articles for article (PubMed ID: 28839232)
1. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors.
Mauro CD; Pesapane A; Formisano L; Rosa R; D'Amato V; Ciciola P; Servetto A; Marciano R; Orsini RC; Monteleone F; Zambrano N; Fontanini G; Servadio A; Pignataro G; Grumetto L; Lavecchia A; Bruzzese D; Iaccarino A; Troncone G; Veneziani BM; Montuori N; Placido S; Bianco R
Sci Rep; 2017 Aug; 7(1):9388. PubMed ID: 28839232
[TBL] [Abstract][Full Text] [Related]
2. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new small molecules targeting the vitronectin-binding site of the urokinase receptor that block cancer cell invasion.
Rea VE; Lavecchia A; Di Giovanni C; Rossi FW; Gorrasi A; Pesapane A; de Paulis A; Ragno P; Montuori N
Mol Cancer Ther; 2013 Aug; 12(8):1402-16. PubMed ID: 23699658
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.
Duriseti S; Goetz DH; Hostetter DR; LeBeau AM; Wei Y; Craik CS
J Biol Chem; 2010 Aug; 285(35):26878-26888. PubMed ID: 20501655
[TBL] [Abstract][Full Text] [Related]
8. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
9. Proteomics Reveals Cell-Surface Urokinase Plasminogen Activator Receptor Expression Impacts Most Hallmarks of Cancer.
Ahn SB; Mohamedali A; Pascovici D; Adhikari S; Sharma S; Nice EC; Baker MS
Proteomics; 2019 Nov; 19(21-22):e1900026. PubMed ID: 31402590
[TBL] [Abstract][Full Text] [Related]
10. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
11. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
12. Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.
van Veen M; Matas-Rico E; van de Wetering K; Leyton-Puig D; Kedziora KM; De Lorenzi V; Stijf-Bultsma Y; van den Broek B; Jalink K; Sidenius N; Perrakis A; Moolenaar WH
Elife; 2017 Aug; 6():. PubMed ID: 28849762
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
14. Aeroallergen Der p 2 promotes motility of human non-small cell lung cancer cells via toll-like receptor-mediated up-regulation of urokinase-type plasminogen activator and integrin/focal adhesion kinase signaling.
Lin CH; Lin HH; Kuo CY; Kao SH
Oncotarget; 2017 Feb; 8(7):11316-11328. PubMed ID: 28076322
[TBL] [Abstract][Full Text] [Related]
15. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
16. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion.
Persson M; Madsen J; Østergaard S; Jensen MM; Jørgensen JT; Juhl K; Lehmann C; Ploug M; Kjaer A
J Nucl Med; 2012 Jan; 53(1):138-45. PubMed ID: 22213823
[TBL] [Abstract][Full Text] [Related]
17. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
[TBL] [Abstract][Full Text] [Related]
19. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis.
Wang Y
Med Res Rev; 2001 Mar; 21(2):146-70. PubMed ID: 11223863
[TBL] [Abstract][Full Text] [Related]
20. Cadmium induces urokinase-type plasminogen activator receptor expression and the cell invasiveness of human gastric cancer cells via the ERK-1/2, NF-κB, and AP-1 signaling pathways.
Khoi PN; Xia Y; Lian S; Kim HD; Kim DH; Joo YE; Chay KO; Kim KK; Jung YD
Int J Oncol; 2014 Oct; 45(4):1760-8. PubMed ID: 25069788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
